Reducing the cost of managing patients with atrial fibrillation undergoing percutaneous coronary intervention with stenting.
Reducing the cost of managing patients with atrial fibrillation undergoing percutaneous coronary intervention with stenting.
J Cardiol. 2020 Aug 26;:
Authors: Mehran R, Vogel B, Levy P
Abstract
Patients undergoing percutaneous coronary intervention (PCI) have an increased risk of both ischemic events and bleeding complications resulting from antithrombotic therapy. These events are particularly common in patients with a concomitant indication for oral anticoagulation, such as those with atrial fibrillation, and are associated with a substantial healthcare resource burden. Advances in procedural aspects of PCI have led to marked improvements in outcomes and a consequent reduction in the costs resulting from PCI-associated complications. Furthermore, recent randomized clinical trials have investigated the optimal antithrombotic strategy in the specific case of patients with atrial fibrillation undergoing PCI, leading to a shift toward the tailoring of antithrombotic therapy according to the patient's individual stroke and bleeding risks. Here we review these recent advances, with a particular focus on the improvements in antithrombotic strategies offered by the non-vitamin K antagonist oral anticoagulants.
PMID: 32859453 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - Category: Cardiology Authors: Mehran R, Vogel B, Levy P Tags: J Cardiol Source Type: research
More News: Angioplasty | Atrial Fibrillation | Bleeding | Cardiology | Clinical Trials | Coronary Angioplasty | Heart | Ischemic Stroke | Percutaneous Coronary Intervention | Stroke | Vitamin K | Vitamins